



SPAFID
CONNECT

Informazione Regolamentata n. 0957-32-2022	Data/Ora Ricezione 02 Maggio 2022 12:55:25	Euronext Milan
--	--	----------------

Societa' : DiaSorin

Identificativo : 161398

Informazione
Regolamentata

Nome utilizzatore : DIASORINN01 - Ulisse Spada - Valerio
Vaccarone

Tipologia : 3.1

Data/Ora Ricezione : 02 Maggio 2022 12:55:25

Data/Ora Inizio : 02 Maggio 2022 12:55:26

Diffusione presunta

Oggetto : Publication of the summary report of the
votes cast

Testo del comunicato

Please see the attachment.



The Diagnostic Specialist

PRESS RELEASE ○○○

DIASORIN: PUBLICATION OF THE SUMMARY REPORT OF THE VOTES CAST

Saluggia, May 2, 2022 – DiaSorin S.p.A. (FTSE MIB: DIA) (the “**Company**”) hereby gives notice that, pursuant to applicable laws and regulations, the summary report of the votes cast at the ordinary meeting of shareholders of the Company, held on April 29, 2022, was made available to the public today on the Company’s corporate website (www.diasoringroup.com, section “Governance”, “Shareholders Meeting”, “2022”).

For additional information, please contact:

Riccardo Fava

Corporate Vice President Communication & Investor Relations

Tel: +39.0161.487988

riccardo.fava@diasorin.it

Emanuela Salvini

Investor Relator

Tel: +39.0161.487567

emanuela.salvini@diasorin.it

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 43 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”. More info at www.diasoringroup.com

Fine Comunicato n.0957-32

Numero di Pagine: 3